Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $8.8 million.

  • Taysha Gene Therapies' Cash from Financing Activities rose 33.39% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.7 million, marking a year-over-year increase of 208.65%. This contributed to the annual value of $76.7 million for FY2024, which is 43.78% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Cash from Financing Activities is $8.8 million, which was down 95.93% from $216.3 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Cash from Financing Activities high stood at $216.3 million for Q2 2025, and its period low was -$4.2 million during Q4 2023.
  • In the last 3 years, Taysha Gene Therapies' Cash from Financing Activities had a median value of $377,000 in 2023 and averaged $39.8 million.
  • Within the past 5 years, the most significant YoY rise in Taysha Gene Therapies' Cash from Financing Activities was 136,637.86% (2023), while the steepest drop was 245.79% (2023).
  • Taysha Gene Therapies' Cash from Financing Activities (Quarterly) stood at $41.2 million in 2022, then slumped by 110.30% to -$4.2 million in 2023, then spiked by 91.60% to -$357,000 in 2024, then soared by 33.39% to $8.8 million in 2025.
  • Its Cash from Financing Activities was $8.8 million in Q3 2025, compared to $216.3 million in Q2 2025 and -$52,000 in Q1 2025.